Cognition Therapeutics

Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The firm develops drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano in 2007 and is headquartered in Purchase, NY.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.

PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that the company would be participating in Needham & Company's 21st Annual Virtual Healthcare Conference being held April 11-14, 2022. The Company's president and CEO, Lisa Ricciardi, will be providing a corporate update on Monday, April 11, 2022 from 3:00 – 3:40 p.m. ET.

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

Cognition Therapeutics, Inc. (CGTX) CEO Lisa Ricciardi on Q4 2021 Results - Earnings Call Transcript

- Well capitalized from $52 million IPO and $169 million in grant funding - - Established clinical program in Alzheimer's disease enhanced by new DLB study and dry AMD program - - Conference call and live audio webcast scheduled for Wednesday, March 30 at 8:00 a.m. ET -

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 (σ-2) receptor modulator in development for Alzheimer's disease and other neurodegenerative disorders. Specifically, data will be presented from the Phase 1b SNAP study (COG0104; NCT03522129) and an interim analysis from the Phase 2 SHINE study (COG0201; NCT03507790) in two posters at the upcoming AD/PD™ 2022: the 16th International Conference on Alzheimer's & Parkinson's Diseases.

Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2022

Anthony Caggiano, M.D., Ph.D., Participating on February 15th Panel: “Exploring the Possibilities of Developing Neurodegenerative Therapeutics” Anthony Caggiano, M.D., Ph.D., Participating on February 15th Panel: “Exploring the Possibilities of Developing Neurodegenerative Therapeutics”

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics

The stock price of Cognition Therapeutics Inc (NASDAQ: CGTX) increased by over 16% during intraday trading today. This is why it happened.

Cognition Therapeutics Stock (CGTX): Why The Price Surged Today

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company's 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

Lisa Ricciardi, CEO, to participate as a Panelist in, “Aduhelm: Stimulating the Next- Generation of AD Treatment” Lisa Ricciardi, CEO, to participate as a Panelist in, “Aduhelm: Stimulating the Next- Generation of AD Treatment”

Cognition Therapeutics to Participate in Next-Generation Alzheimer's Disease Panel at Virtual Biotech Showcase on January 11, 2022

PURCHASE, N.Y., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), will hold a virtual R&D symposium on December 7, 2021, from 10:00am – 12:00pm ET.

Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation

Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small-molecule σ-2 modulators into new indications Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small-molecule σ-2 modulators into new indications

Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights

GitLab

Portillo's

3 Companies That Went Public Last Month

PITTSBURGH, Oct. 12, 2021 /PRNewswire/ --  Pittsburgh Life Science Greenhouse (PLSG) is proud to share that one of its portfolio companies, Cognition Therapeutics, Inc., launched an initial public offering on Friday, October 8, 2021, trading on the Nasdaq Global Market under the ticker symbol "CGTX." Cognition Therapeutics' IPO is expected to generate approximately $45.2 million in gross proceeds.

Pittsburgh Life Sciences Greenhouse Proudly Announces IPO of Portfolio Company Cognition Therapeutics

IsoPlexis Corp

IX Acquisition Corp

Life Time Group Holdings

Nuvei Corp

Schultze Special Purpose Acquisition Corp II - Unit

Eight IPOs joined the public market this past week, joined by ten SPACs. Two companies postponed, both citing market conditions: fitness equipment brand iFIT Health & Fitness and drug developer AEON Biopharma.

U.S. IPO Weekly Recap: Healthcare And Canadian Crosslistings Lead An 8 IPO Week

Cognition Therapeutics Inc.'s stock CGTX, is set to start trading Friday, after the New York-based biopharmaceutical company targeting treatments for central nervous systems disorders said its upsized initial public offering priced at $12 a share, in the middle of the expected range of between $11 and $13 a share. The company said it sold 3.77 million shares in the IPO, up from previous expectations of 3.35 million shares, to raise $45.2 million.

Cognition Therapeutics raised more than $45 million after IPO priced in the middle of the expected range

PURCHASE, N.Y., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the pricing of its upsized initial public offering of 3,768,116 shares of its common stock at a public offering price of $12.00 per share. All of the shares of common stock are being offered by Cognition. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cognition, are expected to be approximately $45.2 million.

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

PURCHASE, N.Y., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced that it has launched an initial public offering of 3,350,000 shares of its common stock. In addition, Cognition expects to grant the underwriters a 45-day option to purchase up to an additional 502,500 shares of its common stock at the public offering price, less the underwriting discount. All of the shares of common stock are being offered by Cognition. The initial public offering price is expected to be between $11.00 and $13.00 per share. Cognition's common stock has been approved for listing on The Nasdaq Global Market under the symbol “CGTX.”

Cognition Therapeutics Announces Launch of its Initial Public Offering

News for Cognition Therapeutics Stock (CGTX)